## **Special Issue**

# Cardiovascular Neuromodulatory Therapy

## Message from the Guest Editors

The role of the autonomic nervous system in chronotropic, inotropic, dromotropic, and lusitropic aspects of cardiac function is known. Thus, it is unsurprising that autonomic dysfunction participates in the development and progression of major cardiovascular diseases, including hypertension. myocardial infarction, heart failure, and sudden cardiac death. In fact, evidence has shown that cardiovascular dysfunction associated with myocardial infarction and heart failure. Although these initial studies are promising, it is essential to advance our knowledge of the cardiovascular autonomic effects of both traditional and new pharmacological therapies, considering their possible pleiotropic effects or the remaining risk, for the development and implementation of precise neuromodulatory therapies. Therefore, this Special Issue is focused on the neuromodulatory effects of drugs and therapies in cardiovascular disease.

### **Guest Editors**

Dr. Maria Claudia Costa Irigoven

Heart Institute (InCor), Hypertension Unit, University of Sao Paulo, Sao Paulo 05403-900, Brazil

Prof. Dr. Kátia De Angelis

Physiology Department, Federal University of Sao Paulo UNIFESP, São Paulo 04023-901, SP, Brazil

### Deadline for manuscript submissions

closed (29 February 2024)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/170241

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





## **Pharmaceutica**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## **Author Benefits**

## Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

